Radiation oncology firm Accuray is directing attention to two large multicenter studies that evaluated the use of its CyberKnife system for treating low- and intermediate-risk prostate cancer.
The studies, which were published in the International Journal of Radiation Oncology, Biology, Physics and European Urology Oncology, found that CyberKnife stereotactic body radiation therapy (SBRT) yielded five-year survival rates of 97% to 100% in low-risk patients and 88% to 97% for intermediate-risk patients.
The results for the low-risk patients were better than the historical 92% to 94% survival rates from conventional radiation therapy and equivalent to low-dose-rate brachytherapy and high-dose-rate brachytherapy, Accuray said. What's more, the survival rates for the intermediate-risk patients were equal to or higher than the 85% to 90% rates reported with conventional radiation therapy, according to the company.
